Metsera declares Novo Nordisk's $10 billion bid superior to Pfizer offer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"
November 4, 2025 9:09 AM ESTNovo Nordisk Amended Proposal Values Metsera at up to $ 86.20 per Share, a Total of Approximately $ 10.0 Billion
Superior to Revised Pfizer Proposal that Valued Metsera at up to $ 70.00 per Share, a Total of Approximately $ 8.1 Billion
Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments for Two Business Days
Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders
... More
